GRAIL will be powered by Illumina’s DNA sequencing technology, and the pan-cancer screening test the company intends to create will make determinations about illness by measuring circulating nucleic acids in blood, according to a news release from the company.
“The holy grail in oncology has been the search for biomarkers that could reliably signal the presence of cancer at an early stage,” Richard Klausner, MD, a director of GRAIL, former Illumina CMO and former director of the National Cancer Institute. “Illumina’s sequencing technology now allows the detection of circulating nucleic acids originating in the cancer cells themselves, a superior approach that provides a direct rather than surrogate measurement.”
The startup’s advisory board is rife with scientific and medical experts from institutions known for pioneering cancer research, including New York-based Memorial Sloan Kettering, Portland-based OregonHealth & ScienceUniversity’s Knight Cancer Institute and Houston-based MD Anderson Cancer Center.
More articles on health IT:
AMA invests $15M to open Silicon Valley healthcare innovation company
Startup Insider: Hometeam
IBM Watson partners with Under Armour for health app
